In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B

Tropical Medicine and International Health

Volumn 15, Issue 1, 2010, Pages 68-76

  Zauli Nascimento, Rogéria C ^a   Miguel, Danilo C ^a   Yokoyama Yasunaka, Jenicer K U ^a   Pereira, Ledice I A ^b   Pelli De Oliveira, Milton A ^b   Ribeiro Dias, Fátima ^b   Dorta, Miriam L ^b   Uliana, Silvia R B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Amphotericin B; Meglumine antimoniate; Sensitivity; Tegumentary leishmaniasis

Indexed keywords

AMPHOTERICIN B; MEGLUMINE ANTIMONATE;

ANTIBODY; CHEMOTHERAPY; DISEASE RESISTANCE; DISEASE VECTOR; INFECTIOUS DISEASE; PARASITE RESISTANCE; PROTOZOAN;

AMASTIGOTE; ARTICLE; BRAZIL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; MACROPHAGE; NONHUMAN; PROMASTIGOTE;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MEGLUMINE; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS;

INDIA;

LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS;

EID: 72349086236     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02414.x     Document Type: Article

References (35)

1. Al-Mohammed HI, Chance ML Bates PA (2005) Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana. Antimicrobial Agents and Chemotherapy 49, 3274 3280.
2. Azeredo-Coutinho RB, Mendonça SC, Callahan H, Portal AC Max G (2007) Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (Glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. Journal of Parasitology 93, 688 693.
3. Bermúdez H, Rojas E, Garcia L, et al. (2006) Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Annals of Tropical Medicine & Parasitology 100, 591 600.
4. Castilho TM, Shaw JJ Floeter-Winter LM (2003) New PCR assay using glucose-6-phosphate dehydrogenase for identification of Leishmania species. Journal of Clinical Microbiology 41, 540 546.
5. Croft SL Coombs GH (2003) Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends in Parasitology 19, 502 508.
6. Croft SL, Sundar S Fairlamb AH (2006) Drug resistance in leishmaniasis. Clinical Microbiology Reviews 19, 111 526.
7. Cupolillo E, Brahim LR, Toaldo CB, et al. (2003) Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil. Journal of Clinical Microbiology 41, 3126 3132.
8. Di Giorgio C, Faraut-Gambarelli F, Imbert A, Minodier P, Gasquet M Dumon H (1999) Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. Journal of Antimicrobial Chemotherapy 44, 71 76.
9. Escobar P, Matu S, Marques C Croft SL (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Tropica 81, 151 157.
10. Grogl M, Thomason TN Franke ED (1992) Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. American Journal of Tropical Medicine and Hygiene 47, 117 126.
11. Jeronimo SM, Oliveira RM, Mackay S, et al. (1994) An urban outbreak of visceral leishmaniasis in Natal, Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene 88, 386 388.
12. Kumar D, Kulshrestha A, Singh R Salotra P (2009) In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrobial Agents and Chemotherapy 53, 835 838.
13. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P Oullette M (2009) Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients co-infected with HIV type 1 and Leishmania infantum. Clinical Infectious Diseases 15, e16 e22.
14. Lainson R Shaw JJ (1998) New World leishmaniasis. The neotropical Leishmania species. In : Topley & Wilson's Microbiology and Microbial Infectious Diseases, ninth edn eds L Collier, A Balows M Sussmann) Hodder Arnold, London, pp. 241 266.
15. Medina-Acosta E Cross GAM (1993) Rapid isolation of DNA from trypanosomatid protozoa using a simple "mini-prep" procedure. Molecular and Biochemical Parasitology 59, 327 329. (Pubitemid 223039691)
16. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK, Mortara RA Uliana SR (2007) Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. Journal of Antimicrobial Chemotherapy 60, 526 534.
17. Murray HW, Berman JD, Davies CR Saravia NG (2005) Advances in Leishmaniasis. Lancet 366, 1561 1577.
18. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR Davidson R (2007) Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Transactions of the Royal Society of Tropical Medicine and Hygiene 101, 19 24.
19. Navin TR, Arana BA, Arana FE, Berman JD Chajón JF (1992) Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. Journal of Infectious Diseases 165, 528 534.
20. Oliveira CC, Lacerda HG, Martins DR, et al. (2004) Changing epidemiology of American cutaneous leishmaniasis (ACL) in Brazil: a disease of the urban-rural interface. Acta Tropica 90, 155 162.
21. Palacios R, Osorio LE, Grajalew LF Ochoa MT (2001) Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. American Journal of Tropical Medicine and Hygiene 64, 187 193.
22. Ramos CS, Franco FA, Smith DF Uliana SR (2004) Characterisation of a new Leishmania META gene and genomic analysis of the META cluster. FEMS Microbiology Letters. 238, 213 219.
23. Rijal S, Chappuis F, Singh R, et al. (2003) Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Transactions of the Royal Society of Tropical Medicine and Hygiene 97, 350 354.
24. Reithinger R Dujardin JC (2007) Molecular diagnosis of leishmaniasis: current status and future applications. Journal of Clinical Microbiology 45, 21 25.
25. Robledo SM, Valencia AZ Saravia NG (1999) Sensitivity to Glucantime of Leishmania Viannia isolated from patients prior to treatment. Journal of Parasitology 85, 360 366.
26. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M Saravia NG (2006) Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. The Journal of Infectious Diseases 193, 1375 1383.
27. Romero GA, Guerra MV, Paes MG Macêdo VO (2001) Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. American Journal of Tropical Medicine and Hygiene 65, 456 465.
28. Sharief AH, Gasim Khalil EA, Theander TG, Kharazmi A, Omer SA Ibrahim ME (2006) Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates. Experimental Parasitology 114, 247 252.
29. Silva ES, Gontijo CMF, Pacheco RS, Fiuza VO Brazil RP (2001) Visceral leishmaniasis in the Metropolitan Region of Belo Horizonte, State of Minas Gerais, Brazil. Memórias do Instituto Oswaldo Cruz 96, 285 291.
30. Sundar S, Gupta LB, Rastogi V, Agrawal G Murray HW (2000) Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 94, 200 204.
31. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC Amato Neto V (2008) Treatment of New World cutaneous leishmaniasis - a systematic review with a meta-analysis. International Journal of Dermatology 47, 109 124.
32. Uliana SR, Nelson K, Beverley SM, Camargo EP Floeter-Winter LM (1994) Discrimination amongst Leishmania by polymerase chain reaction and hybridization with small subunit ribosomal DNA derived oligonucleotides. The Journal of Eukaryotic Microbiology 41, 324 330.
33. Yardley V Croft SL (1997) Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrobial Agents and Chemotherapy 41, 752 756.
34. Yardley V, Ortuno N, Llanos-Cuentas A, et al. (2006) American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? The Journal of Infectious Diseases 194, 1168 1175.
35. Zamboni DS Rabinovitch M (2003) Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages. Infection and Immunity 71, 1225 1233.